Results 1 to 10 of about 189,690 (343)

Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib. [PDF]

Medicina (Kaunas)
Background and Objectives: Erlotinib, a tyrosine kinase inhibitor (TKI), is an established therapy for patients with metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations.
Yıldız O, Aykut T, Kaya BE, Genç Ö, Gürbüz AF, Saçkan F, Eryılmaz MK, Koçak MZ, Araz M, Artaç M.   +9 more
europepmc   +2 more sources

The Beta-Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants. [PDF]

Clin Transl Sci
Previous pharmacogenetic findings for beta‐blocker pharmacodynamic candidate genes (ADRB1, ADRB2, ADRA2C, GRK4, and GRK5) have been inconsistent. Therefore, the purpose of this study was to determine whether interactions of pharmacodynamic variants with ...
Luzum JA, Littleton SDR, Lopez-Medina AI, Liu B, She R, Lanfear DE.   +5 more
europepmc   +2 more sources

Persistent Beta-Blocker Therapy Reduces Long-Term Mortality in Patients With Acute Ischemic Stroke With Elevated Heart Rates. [PDF]

J Am Heart Assoc
Background Elevated heart rate in patients with acute ischemic stroke is associated with increased risk of mortality. Beta‐blocker therapy is well known to reduce heart rate.
Lee KJ, Kim SE, Guk HS, Kim DY, Kim BJ, Han MK, Kim JT, Choi KH, Shin DI, Cha JK, Kim DH, Kim DE, Park JM, Kang K, Lee SJ, Kim JG, Oh MS, Yu KH, Lee BC, Hong KS, Cho YJ, Choi JC, Park TH, Park SS, Kwon JH, Kim WJ, Lee J, Lee KB, Sohn SI, Hong JH, Ryu WS, Roh SY, Lee JS, Lee J, Gorelick PB, Bae HJ, of the CRCS‐K (Clinical Research Collaboration for Stroke in Korea) investigators.   +36 more
europepmc   +2 more sources

Lower In‐Hospital Mortality With Beta‐Blocker Use at Admission in Patients With Acute Decompensated Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background It remains unclear whether beta‐blocker use at hospital admission is associated with better in‐hospital outcomes in patients with acute decompensated heart failure.
Yodo Tamaki, Hidenori Yaku, Takeshi Morimoto, Yasutaka Inuzuka, Neiko Ozasa, Erika Yamamoto, Yusuke Yoshikawa, Makoto Miyake, Hirokazu Kondo, Toshihiro Tamura, Takeshi Kitai, Moritake Iguchi, Kazuya Nagao, Ryusuke Nishikawa, Yuichi Kawase, Takashi Morinaga, Mitsunori Kawato, Mamoru Toyofuku, Yukihito Sato, Koichiro Kuwahara, Yoshihisa Nakagawa, Takao Kato, Takeshi Kimura   +22 more
doaj   +1 more source

The Association of Beta-Blocker Use and Bone Mineral Density Level in Hemodialysis Patients: A Cross-Sectional Study

Medicina, 2023
Background and Objectives: Osteoporosis results in increasing morbidity and mortality in hemodialysis patients. The medication for treatment has been limited.
Suthiya Anumas, Saranya Thitisuriyarax, Pichaya Tantiyavarong, Waroot Pholsawatchai, Pattharawin Pattharanitima   +4 more
doaj   +1 more source

A Clinical-Epidemiological Study on Beta-Blocker Poisonings Based on the Type of Drug Overdose

Journal of Toxicology, 2023
Background. Beta‐blockers carry a high risk of potentially causing fatal poisoning if overdosed. We aimed to assess the clinical and epidemiological characteristics of patients with beta-blocker poisoning. Methods.
Nastaran Eizadi-Mood, Mahtab Adib, Arman Otroshi, Gholamali Dorooshi, Rokhsareh Meamar   +4 more
doaj   +1 more source

Beta-blockers for hypertension [PDF]

Cochrane Database of Systematic Reviews, 2017
Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long-term beneficial effects on mortality and cardiovascular disease (CVD) when used in people with heart failure or acute myocardial infarction. Beta-blockers were thought to have similar beneficial effects when used as first-line
Wiysonge, Charles S., Bradley, H. A., Volmink, J., Mayosi, B. M., Opie, L. H.   +4 more
openaire   +3 more sources

Beta-blocker use and up-titration after acute ST-segment elevation myocardial infarction: a cohort study

Swiss Medical Weekly, 2020
BACKGROUND The European Society of Cardiology recommends beta-blocker prescription after ST-segment elevation myocardial infarction (STEMI).
Christel Bruggmann, Stéphane Fournier, Alice Panchaud, Olivier Muller, Farshid Sadeghipour, Pierre Voirol   +5 more
doaj   +1 more source

Impact of beta‐blocker use on the long‐term outcomes of heart failure patients with chronic obstructive pulmonary disease

ESC Heart Failure, 2021
Aims The number of patients with both chronic obstructive pulmonary disease (COPD) and heart failure (HF) is increasing in Asia, and these conditions often coexist.
Yoshiaki Kubota, Wan Ting Tay, Tiew‐Hwa Katherine Teng, Kuniya Asai, Takashi Noda, Kengo Kusano, Atsushi Suzuki, Nobuhisa Hagiwara, Shinji Hisatake, Takanori Ikeda, Ryobun Yasuoka, Takashi Kurita, Wataru Shimizu, ASIAN‐HF Executive Committee   +13 more
doaj   +1 more source

Beta‐blocker use and mortality among patients with systolic heart failure and pacemaker rhythm

ESC Heart Failure, 2023
Aims Beta‐blockers are proven to improve survival among patients with heart failure with reduced ejection fraction. Their efficacy in patients with heart failure with reduced ejection fraction and pacemaker devices has not been demonstrated.
Andrew S. Perry, Aldo P. Maggioni, Luigi Tavazzi, Wayne C. Levy   +3 more
doaj   +1 more source